{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:38:11Z","timestamp":1783960691821,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejmech.2024.116663","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T08:18:52Z","timestamp":1721290732000},"page":"116663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia"],"prefix":"10.1016","volume":"276","author":[{"given":"Enqiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairui","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2106","authenticated-orcid":false,"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116663_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116663_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116663_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116663_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116663_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116663_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116663_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ejmech.2024.116663_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116663_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116663_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2024.116663_bib11","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116663_bib12","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.febslet.2010.04.002","article-title":"The molecular signature of oncofusion proteins in acute myeloid leukemia","volume":"584","author":"Martens","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.116663_bib13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/stem.3263","article-title":"Clinical and molecular consequences of fusion genes in myeloid malignancies","volume":"38","author":"Matsukawa","year":"2020","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2024.116663_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fgene.2019.00133","article-title":"Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity","volume":"10","author":"Goldman","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejmech.2024.116663_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116663_bib16","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2024.116663_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2023.100010","article-title":"Structure, functions, and recent advances in the development of SIRT2 inhibitors","volume":"1","author":"Xue","year":"2023","journal-title":"Pharm. Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.116663_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2024.116663_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116663_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-015-0413-6","article-title":"Panobinostat: a review in relapsed or refractory multiple myeloma","volume":"11","author":"Greig","year":"2016","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2024.116663_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: a novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2024.116663_bib22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1039\/C4MD00350K","article-title":"Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment","volume":"5","author":"Pan","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2024.116663_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients","volume":"30","author":"Mozzetta","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116663_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13046-020-01792-8","article-title":"Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway","volume":"39","author":"Wang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.ejmech.2024.116663_bib25","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/ijms21228828","article-title":"Structure-based inhibitor discovery of class I histone deacetylases (HDACs)","volume":"21","author":"Luo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116663_bib26","first-page":"757","article-title":"Medicinal chemistry advances in targeting class I histone deacetylases, Explor. Target","volume":"4","author":"Abdallah","year":"2023","journal-title":"Anti-Tumor Ther."},{"key":"10.1016\/j.ejmech.2024.116663_bib27","article-title":"Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116663_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1289\/ehp.834927","article-title":"Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines","volume":"49","author":"Mulder","year":"1983","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.ejmech.2024.116663_bib29","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116663_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.1c01472","article-title":"Potent hydrazide-based HDAC inhibitors with a superior pharmacokinetic profile for efficient treatment of acute myeloid leukemia in vivo","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116663_bib31","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on Panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116663_bib32","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/acs.jmedchem.8b00136","article-title":"Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116663_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","article-title":"Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.116663_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejmech.2024.116663_bib35","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116663_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-022-01306-7","article-title":"Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression","volume":"14","author":"Cao","year":"2022","journal-title":"Clin. Epigenet."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424005439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424005439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:48:28Z","timestamp":1730738908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424005439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"alternative-id":["S0223523424005439"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116663","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116663"}}